Brand Name

Plavix

Generic Name
Clopidogrel
View Brand Information
FDA approval date: November 17, 1997
Classification: P2Y12 Platelet Inhibitor
Form: Tablet

What is Plavix (Clopidogrel)?

For people who have suffered a heart attack, stroke, or have certain heart or blood vessel conditions, one of the biggest fears is having another cardiovascular event. Blood clots are a major cause of these life-threatening incidents. Plavix (clopidogrel) helps reduce that risk, giving patients greater confidence as they recover and return to daily life. 

Plavix is an antiplatelet medication that helps prevent platelets in the blood from sticking together and forming harmful clots. It belongs to a drug class called P2Y12 platelet inhibitors. This medication has been widely prescribed for over two decades and is a cornerstone of modern cardiovascular care. It’s often used after heart attacks, strokes, or certain heart procedures like stent placement. By keeping blood flowing smoothly, Plavix helps protect against future heart or brain-related complications. 

What does Plavix do? 

Plavix is used to prevent blood clots in people with heart and circulatory conditions that increase their risk of serious cardiovascular events. It is often prescribed for: 

  • People who have had a recent heart attack (myocardial infarction) or stroke 
     
  • Those with peripheral arterial disease (PAD), a condition that narrows the blood vessels in the legs or arms 
     
  • Patients who have had coronary stents or bypass surgery to keep blood vessels open 

Plavix doesn’t dissolve existing clots; instead, it prevents new ones from forming. This helps lower the risk of heart attack, ischemic stroke, or vascular death in high-risk patients. 

In clinical studies, Plavix has been shown to significantly reduce the risk of major cardiovascular events compared with aspirin alone (FDA, 2024). Many patients experience improved peace of mind and better long-term outcomes when taking the medication as part of a comprehensive heart health plan. 

How does Plavix work? 

To understand how Plavix works, it helps to know how blood clots form. Platelets, tiny cell fragments in the blood, are responsible for clumping together when a blood vessel is injured, forming a clot to stop bleeding. However, in people with certain heart or vascular conditions, platelets can clump unnecessarily, creating dangerous clots that block arteries in the heart or brain. 

Plavix works by blocking a specific receptor on platelets known as P2Y12. This receptor normally binds to a substance called ADP (adenosine diphosphate), which signals platelets to stick together. By preventing this binding, Plavix reduces platelet activation and aggregation. In simple terms, it keeps the blood “slippery” and less likely to clot. 

This mechanism is clinically important because clot prevention helps maintain healthy blood flow to the heart and brain, reducing the risk of heart attack and stroke. The effect is long-lasting but reversible meaning normal clotting ability returns a few days after the medication is stopped. This balance helps ensure both safety and effectiveness in long-term treatment. 

Plavix side effects 

Like all medications, Plavix can cause side effects, though most people tolerate it well. The most common concern is bleeding, since the drug reduces the blood’s ability to clot. 

Common side effects may include: 

  • Easy bruising 
     
  • Nosebleeds or prolonged bleeding from cuts 
     
  • Diarrhea or stomach upset 
     
  • Mild rash or itching 

Serious side effects (less common): 

  • Severe or unexplained bleeding (such as black or bloody stools, blood in urine, or vomiting blood) 
     
  • Unusual tiredness or weakness (may signal anemia) 
     
  • Severe headache, vision changes, or confusion (possible signs of bleeding in the brain) 
     
  • Allergic reactions, including rash, swelling, or difficulty breathing 

Plavix can rarely cause serious TTP, characterized by small blood clots and symptoms like fever, pale skin, purple spots, or jaundice. Seek emergency care if these occur.  

Avoid or use caution with Plavix if you have active bleeding, recent surgery, severe liver disease, or a clopidogrel allergy. Discuss all medications with your doctor, as some, like NSAIDs or warfarin, increase bleeding risk. 

Plavix dosage 

Plavix is a daily oral tablet, taken with or without food. It’s often prescribed long-term after heart attack, stroke, or stent procedures to prevent recurrence, sometimes with aspirin as dual antiplatelet therapy (DAPT) for stronger clot prevention. Take it consistently; stopping suddenly, especially after stent placement, greatly increases dangerous clot risk. 

Doctors may order periodic blood tests to monitor for anemia or liver changes and to ensure the medication is working properly. Older adults and those with kidney or liver problems usually don’t require dose adjustments, but close monitoring is advised. 

If you miss a dose, take it as soon as you remember unless it’s almost time for your next dose never double up to make up for a missed tablet. 

Does Plavix have a generic version? 

Yes. Clopidogrel, the generic form of Plavix, is FDA-approved and widely available in the United States and many other countries. Generic clopidogrel contains the same active ingredient, dosage strength, safety, and effectiveness as brand-name Plavix. 

Most pharmacies dispense the more affordable generic clopidogrel unless otherwise specified by a doctor. Patients can trust that switching between Plavix and generic clopidogrel won’t impact the medication’s effectiveness when taken as prescribed. Plavix was FDA-approved in 1997, and its generic followed in 2012; both remain widely used in cardiology. 

Conclusion 

Plavix (clopidogrel) is a proven, life-saving medication that helps prevent heart attacks, strokes, and other complications caused by blood clots. By keeping platelets from sticking together, it ensures steady blood flow to vital organs and reduces the risk of future cardiovascular events. 

Despite a possible bleeding risk, Plavix, with medical supervision, is a safe and effective option for many, supporting millions globally in their recovery and heart health. Take it as directed, attend follow-ups, and discuss concerns with your doctor to help you live a longer, healthier life. 

References 

  1. U.S. Food and Drug Administration (FDA). (2024). Plavix (clopidogrel) prescribing information. Retrieved from https://www.accessdata.fda.gov 
     
  1. Mayo Clinic. (2024). Clopidogrel (oral route) drug information. Retrieved from https://www.mayoclinic.org 
     
  1. MedlinePlus. (2024). Clopidogrel: Uses, dosage, and side effects. National Library of Medicine. Retrieved from https://medlineplus.gov 
     
  1. National Institutes of Health (NIH). (2024). Antiplatelet therapy and prevention of cardiovascular disease. Retrieved from https://www.nih.gov 

Top Global Experts

There are no experts for this drug

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

There is no latest advances for this treatment

Brand Information

Plavix (clopidogrel)
1DOSAGE FORMS AND STRENGTHS
  • 75 mg tablets: Pink, round, biconvex, film-coated tablets debossed with "75" on one side and "1171" on the other
  • 300 mg tablets: Pink, oblong, film-coated tablets debossed with "300" on one side and "1332" on the other
2ADVERSE REACTIONS
The following serious adverse reactions are discussed below and elsewhere in the labeling:
  • Bleeding
  • Thrombotic thrombocytopenic purpura
2.1Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions and durations of follow-up, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Plavix has been evaluated for safety in more than 54,000 patients, including over 21,000 patients treated for one year or more. The clinically important adverse reactions observed in trials comparing Plavix plus aspirin to placebo plus aspirin and trials comparing Plavix alone to aspirin alone are discussed below.
2.2Postmarketing Experience
The following adverse reactions have been identified during postapproval use of Plavix. Because these reactions are reported voluntarily from a population of an unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Hemorrhages, including those with fatal outcome, have been reported in patients treated with Plavix.
  • Blood and lymphatic system disorders: Agranulocytosis, aplastic anemia/pancytopenia, thrombotic thrombocytopenic purpura (TTP), acquired hemophilia A
  • Gastrointestinal disorders: Colitis (including ulcerative or lymphocytic colitis), pancreatitis, stomatitis, gastric/duodenal ulcer, diarrhea
  • General disorders and administration site condition: Fever
  • Hepatobiliary disorders: Acute liver failure, hepatitis (noninfectious), abnormal liver function test
  • Immune system disorders: Hypersensitivity reactions, anaphylactoid reactions, serum sickness, insulin autoimmune syndrome, which can lead to severe hypoglycemia
  • Musculoskeletal, connective tissue and bone disorders: Myalgia, arthralgia, arthritis
  • Nervous system disorders: Taste disorders, headache, ageusia
  • Psychiatric disorders: Confusion, hallucinations
  • Respiratory, thoracic and mediastinal disorders: Bronchospasm, interstitial pneumonitis, eosinophilic pneumonia
  • Renal and urinary disorders: Increased creatinine levels
  • Skin and subcutaneous tissue disorders: Maculopapular, erythematous or exfoliative rash, urticaria, bullous dermatitis, eczema, toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis (AGEP), angioedema, drug-induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), erythema multiforme, lichen planus, generalized pruritus
  • Vascular disorders: Vasculitis, hypotension
3OVERDOSAGE
Platelet inhibition by Plavix is irreversible and will last for the life of the platelet. Overdose following clopidogrel administration may result in bleeding complications. A single oral dose of clopidogrel at 1500 or 2000 mg/kg was lethal to mice and to rats and at 3000 mg/kg to baboons. Symptoms of acute toxicity were vomiting, prostration, difficult breathing, and gastrointestinal hemorrhage in animals.
Based on biological plausibility, platelet transfusion may restore clotting ability.
4DESCRIPTION
Plavix (clopidogrel tablets) is a thienopyridine class inhibitor of P2Y
The structural formula is as follows:
Chemical Structure
Clopidogrel bisulfate is a white to off-white powder. It is practically insoluble in water at neutral pH but freely soluble at pH 1. It also dissolves freely in methanol, dissolves sparingly in methylene chloride, and is practically insoluble in ethyl ether. It has a specific optical rotation of about +56°.
Plavix for oral administration is provided as either pink, round, biconvex, debossed, film-coated tablets containing 97.875 mg of clopidogrel bisulfate which is the molar equivalent of 75 mg of clopidogrel base or pink, oblong, debossed, film-coated tablets containing 391.5 mg of clopidogrel bisulfate which is the molar equivalent of 300 mg of clopidogrel base.
Each tablet contains hydrogenated castor oil, hydroxypropyl cellulose, mannitol, microcrystalline cellulose, and polyethylene glycol 6000 as inactive ingredients. The pink film coating contains ferric oxide, hypromellose 2910, lactose monohydrate, titanium dioxide, and triacetin. The tablets are polished with Carnauba wax.
5HOW SUPPLIED/STORAGE AND HANDLING
Plavix (clopidogrel tablets) 75 mg are available as pink, round, biconvex, film-coated tablets debossed with "75" on one side and "1171" on the other. Tablets are provided as follows:
Plavix (clopidogrel tablets) 300 mg are available as pink, oblong, film-coated tablets debossed with "300" on one side and "1332" on the other. Tablets are provided as follows:
6PATIENT COUNSELING INFORMATION
Advise patients to read FDA approved patient labeling (Medication Guide).
7PRINCIPAL DISPLAY PANEL - 75 mg Tablet Bottle Label
NDC 0024-1171-90
Plavix
75 mg
Dispense with
90 Tablets
PRINCIPAL DISPLAY PANEL - 75 mg Tablet Bottle Label
8PRINCIPAL DISPLAY PANEL - 300 mg Tablet Blister Pack Carton
NDC 0024-1332-30
Plavix
30 film-coated tablets
PRINCIPAL DISPLAY PANEL - 300 mg Tablet Blister Pack Carton